钙模拟剂时代前后终末期肾病相关甲状旁腺功能亢进的治疗策略
本研究基于澳大利亚终末期肾病人群,按甲状旁腺切除术日期分为钙模拟剂前、钙模拟剂时代及西那卡塞补贴取消后三组,比较从透析开始至手术的时间及手术率趋势。结果显示手术率随年份增加,钙模拟剂时代有下降趋势,术前甲状旁腺激素水平显著升高,提示手术延迟和疾病严重度增加。
要点
- 甲状旁腺切除术率随西那卡塞可及性变化而波动。
- 钙模拟剂补贴取消后术前PTH水平显著升高。
- 手术延迟可能反映疾病严重度增加。
核心结论
- 甲状旁腺切除术率似乎随西那卡塞的可及性而变化。
- 治疗策略的改变伴随术前甲状旁腺激素水平升高,反映手术延迟和疾病严重度增加。
研究设计与样本
- 回顾性队列研究,根据甲状旁腺切除术日期分为三组:A组钙模拟剂前、B组钙模拟剂时代、C组西那卡塞补贴取消后。
- 1998年至2016年间共实施195例甲状旁腺切除术。
- 主要结局为从透析开始至甲状旁腺切除术的时间,采用回归分析 examine 手术率趋势。
主要发现
- 从透析开始至转诊的中位时间:A组69(33-123)个月,B组67(31-110)个月,C组44(23-102)个月(P = .55)。
- 甲状旁腺切除术率逐年增加(CI 0.09-1.13,R2=0.27,P = .02)。
- 钙模拟剂时代手术率有下降趋势(P = .08)。
- 术前中位甲状旁腺激素水平显著升高:A组842(418-1,553)pg/mL,B组1,040(564-1,810)pg/mL,C组1,350(1,037-1,923)pg/mL(P < .01)。
临床怎么用
- 临床需关注西那卡塞可及性变化对甲状旁腺切除术时机的影响。
- 术前PTH水平升高提示手术延迟,应评估疾病严重度并适时转诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 2004, end-stage renal disease related hyperparathyroidism patients are treated mainly with cinacalcet, which ceased to be subsidized through the Australian Pharmaceutical Benefits Scheme in 2015. We aimed to investigate the impact of these changes on the treatment strategy in the Australian end-stage renal disease population. METHODS: The following groups were formed according to the date of parathyroidectomy: A, before calcimimetics; B, during the era of calcimimetics; and C, after cinacalcet removal by the Australian Pharmaceutical Benefits Scheme. The primary outcome was time from start of dialysis to parathyroidectomy. Regression analysis was used to examine trends in parathyroidectomy rates. RESULTS: Between 1998 and 2016, 195 parathyroidectomies were performed. Median time to referral was 69 (33-123), 67 (31-110) and 44 (23-102) months for groups A, B, and C, respectively (P = .55). Parathyroidectomy rates increased throughout the years (CI 0.09-1.13, R2=0.27, P = .02). A trend toward a dip in parathyroidectomy rates was seen during the era of cinacalcet (P = .08). Median preoperative parathyroid hormone levels increased significantly (842 [418-1,553] versus 1,040 [564-1,810] versus 1,350 [1,037-1,923] pg/mL, for groups A, B, and C, respectively [P < .01]). CONCLUSION: Parathyroidectomy rates seem to vary according to the availability of cinacalcet. This change in treatment strategy is accompanied with increased preoperative parathyroid hormone levels, reflecting delayed surgery and increased disease severity.
引用
- van der Plas WY, Engelsman AF, Umakanthan M, et al. Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. Surgery. 2018. PMID: 30413324. doi:10.1016/j.surg.2018.04.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。